Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation.

What Was Tested

This randomized controlled trial looks at CGRP (Calcitonin Gene-Related Peptide) in the context of migraine.

Their objective was to investigate whether sildenafil could induce migraine attacks in individuals with migraine pre-treated with the CGRP-receptor antibody erenumab.

Why It Was Studied

The cAMP and cGMP pathways are implicated in the initiation of migraine attacks, but their interactions remain unclear.

Calcitonin gene-related peptide (CGRP) triggers migraine attacks via cAMP, whereas the phosphodiesterase-5 inhibitor sildenafil induces migraine attacks via cGMP.

Who Took Part

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The participants were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received CGRP (Calcitonin Gene-Related Peptide).

A placebo (an inactive look-alike) gave the CGRP (Calcitonin Gene-Related Peptide) group a baseline to be compared against.

Each person switched between CGRP (Calcitonin Gene-Related Peptide) and the comparison at some point, usually with a gap in between.

The primary endpoint was the difference in the incidence of migraine attacks between sildenafil and placebo during the 12-h observation period after administration.

What Was Measured

The subject headings attached to it are Sildenafil Citrate, Receptors, Calcitonin Gene-Related Peptide, Migraine Disorders, Cyclic GMP, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists and Phosphodiesterase 5 Inhibitors.

Author keywords: CGRP, PDE-5, cGMP, human models and trigeminovascular system.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Cephalalgia : an international journal of headache), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.